Tag Archives: European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS)

New Cancer Drugs Often Bestow Little Benefit Regarding Survival or Wellbeing (NHS Choices / BMJ)

Posted on October 15, 2017 by Dementia and Elderly Care News

Summary A quotation from the authors’ abstract may say it all: “This systematic evaluation of oncology approvals by the European Medicines Agency (EMA) in 2009-13 shows that most drugs entered the market without evidence of benefit on survival or quality … Continue reading →

Posted in Commissioning, For Doctors (mostly), For Nurses and Therapists (mostly), For Social Workers (mostly), In the News, International, Management of Condition, NHS Digital (Previously NHS Choices), Pharmacological Treatments, Quick Insights, Statistics, Systematic Reviews, UK, Universal Interest | Tagged Assessment of Quality of Life, Bazian, Behind the Headlines, Better Regulation, Big Pharma, BMJ Publishing Group Ltd, British Medical Journal (BMJ), Cancer, Cancer Drugs Approved by EMA (2009-13), Cancer Drugs Approved on Basis of Surrogate End Points, Cancer Drugs Fund (CDF), Cancer Pharmaceuticals (New Approvals), Cancer Research, Cancer Survival, Cancer Survival Group: London School of Hygiene and Tropical Medicine, Cancer Treatment (Newer Drugs), Department of Global Health and Social Medicine: King's College London, Department of Health Policy: London School of Economics and Political Science, Department of Health Services Research and Policy: London School of Hygiene and Tropical Medicine, Drug Regulation, EMA: European Medicines Agency, European Medicines Agency, European Medicines Agency (Cancer Drug Approvals), European Medicines Agency (EMA), European Public Assessment Reports (EPARs), European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS), European Society for Medical Oncology's Magnitude of Clinical Benefit Scale (MCBS), Evidence Versus Mythology, Faculty of Pharmacy: Riga Stradins University, Institute of Cancer Policy: King's College London, Kings College London, Latvia, London, London School of Economics and Political Science, London School of Hygiene and Tropical Medicine, London School of Hygiene and Tropical Medicine (LSHTM), LSE Health: London School of Economics and Political Science, LSHTM: London School of Hygiene and Tropical Medicine, Market Approval (New Cancer Drugs), Myth-Busting, Myths and Misconceptions About New Cancer Drugs, New Cancer Drug Approvals (EMA), Pharmaceutical Industry, Pharmaceutical Regulators, Pharmaceuticals, Quality of Life, Regulatory Experts, Regulatory Requirements, Regulatory Stringency, Regulatory System, Riga Stradins University (Latvia), Surrogate End Points Versus Subsequent Efficacy / Survival, Thinking Like a Patient and Acting Like a Taxpayer | Leave a comment

Tag Archives: European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS)

Recent Posts

Archives

Categories

Google Translate (100+ Languages)

Recommended Sites